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 Abstract
 Introduction: Since 2002, with the creation of Centers of Memory Resources and Research 
(CMRR), considerable progress has been made in France regarding the administrative and in-
stitutional framework within which Alzheimer’s disease (AD) is managed. In this study, we ex-
plore three approaches that can help optimize the inclusion of patients in clinical trials re-
lated to AD. They are as follows: to assess communication concerning clinical trials on AD in 
French CMRR, to analyze the internal organization of these centers concerning the dynamics 
of inclusion, and to evaluate screening tools used.  Methods: A national, descriptive, cross-
sectional survey was conducted in all CMRR in France between May 1 and July 31, 2011, using 
a self-administered questionnaire. All investigators, subinvestigators and the relevant CMRR 
personnel were involved.  Results: A total of 75% of the CMRR participated, and about 30% of 
the physicians contacted responded positively to the survey. Only 50% reported having com-
municated with health care professionals at least once in the previous 3 months, and less than 
50% had communicated occasionally with the general public. A total of 75% of those surveyed 
had a research group but only half of the groups were active, 50% of the physicians did not 
have a consultation time dedicated to study recruitment, and 75% of the respondents had a 
screening tool in their CMRR but over half of them were not satisfied with it.  Conclusion: This 
investigation provides a basis for improving the screening of patients by both internal orga-
 Published online: November 1, 2013 
E X T R A
 Prof. Thierry Dantoine
 Université de Limoges
 EA 6310 HAVAE Handicap Autonomie Vieillissement Activité Environnement
 FR–87025 Limoges (France)
 E-Mail thierry.dantoine  @  chu-limoges.fr 
www.karger.com/dee
 DOI: 10.1159/000353891 
This is an Open Access article licensed under the terms of the Creative Commons Attribution-
NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to 
the online version of the article only. Distribution permitted for non-commercial purposes only.
D
ow
nl
oa
de
d 
by
: 
H
ar
va
rd
 U
ni
ve
rs
ity
   
   
   
   
   
   
   
   
   
   
   
   
 
12
8.
10
3.
13
8.
2 
- 1
1/
19
/2
01
3 
10
:3
5:
51
 P
M
418Dement Geriatr Cogn Disord Extra 2013;3:417–425
 DOI: 10.1159/000353891 
E X T R A
 Tchalla et al.: Optimization of the Inclusion of Alzheimer’s Disease Patients in Clinical 
Trials 
www.karger.com/dee
© 2013 S. Karger AG, Basel
nizational development and adaptation of tools already available. Improvement requires pro-
moting regular communication that is appropriate and targeted to health care professionals, 
smaller memory centers, associations and the public, and therefore, familiarizing the whole 
population with clinical research on AD.  © 2013 S. Karger AG, Basel
 Introduction
 Dementia is one of the most common and one of the most serious neurological disor - 
ders – particularly given the aging population. It is estimated that the number of people with 
dementia globally increased from approximately 24 million in 2000 to nearly 35.6 million in 
2010, and that this number doubles every 20 years  [1, 2] . Alzheimer’s disease (AD) and 
related dementias represent a major challenge for health care systems in the aging popu-
lation  [1] . AD is particularly devastating in that there is no cure and no way to prevent it or 
slow its progression. It was estimated that in the USA, at least 11 million of individuals are 
expected to suffer from AD by the middle of the century and 6 million in Europe  [2, 3] . In the 
UK, the number of individuals with dementia is approaching 700,000, with more than half of 
them suffering from AD  [3] . Researchers estimate that by 2050, 115 million subjects will 
suffer from AD worldwide. Therefore, the estimated AD-related health care costs will become 
unsustainable. In 2010, the cost of dementia was globally estimated to USD 604 billion  [4, 5] . 
Moreover, there remains the need to preserve the independence, autonomy and quality of life 
of elderly subjects with AD as long as possible and to relieve the burden of care experienced 
by informal caregivers. 
 In France, the results of the PAQUID study revealed that 857,000 individuals aged 65 and 
over (8.7%) had dementia, 80% were suffering from AD. It is estimated that over 225,000 
new cases occur each year (2.3% of the population aged 65 and over)  [6] . This increase in the 
number of patients is not without consequences. Among the problems that have emerged are 
the ethical difficulty of making a very early diagnosis despite advances in biomarkers, the 
absence of an effective ‘disease-modifying’ therapy, and difficulties with assisting patients 
and their caregivers. Thus, the scientific community is confronted with the challenge of accel-
erating research, often using multicenter clinical trials with an international dimension, 
leading to high stakes. 
 France has been the second European country behind Scandinavia in terms of recruiting 
patients (400 patients/million people) for all pathologies  [7] . Notably in the field of neuro-
science and AD, France has lost this place according to investigations by pharmaceutical 
companies performed in 2008. In 2010, France was far behind, with an average number of 
27.7 recruited patients per study compared to 40.2 in Scandinavia and below the overall 
European figure of 28.2. With respect to the average speed, France is far behind Scandinavia 
at 0.7 versus 2.0, and below the European figure of 1.2  [8] . Since 2002, with the creation of 
Centers of Memory Resources and Research (CMRR) considerable improvements have been 
made in the administrative and institutional framework within which dementia is managed. 
Progress has been achieved by improving local organization, sharing experiences and estab-
lishing a national investigator network as it had already been done for the AD plan, which is 
strongly encouraging. The most emblematic change took place in March 2007 with the 
creation of a public interest group (GIP) supported by Interregional Clinical Research Delega-
tions (DIRC) and known as the National Center for Managing Health Product Trials (CeNGEPS) 
lasting for a period of 4 years. Its objective was to maintain and increase the attractiveness 
of France for the conduct of clinical research  [9, 10] . 
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 The main aim of the present study was to look at factors that optimize inclusion in 
clinical trials on AD. Specific objectives were primarily to assess how the CMRR facilitate 
communication concerning clinical trials, to evaluate the internal organization of centers as 
it affects the dynamics of subject recruitment, and to evaluate the screening tools used in 
each CMRR.
 Methods
 Study Design
 This was a descriptive national epidemiological survey involving all CMRR in France. 
This study was not interventional in that it did not affect the care of patients in the centers.
 Study Framework
 A CMRR is a center of memory resources and research that meets the criteria of the DHOS 
Circular of April 16, 2002, on the implementation of the action program for patients with AD 
or related conditions. Each CMRR is the subject of proceedings for certification by the regional 
hospital agencies. Currently, there are 27 CMRR in France including 25 in metropolitan areas. 
They have four missions: care, education, research and an entertainment network.
 Study Population
 The target population for this study consisted mainly of doctors, physician investigators 
and subinvestigators in all CMRR in France. To participate in the survey, subjects were 
required to be medically registered and to have worked for at least 1 year in a CMRR. Responses 
to the questionnaire received after the study period were excluded.
 Conduct of the Survey
 The survey was conducted over 3 months between May 1 and July 31, 2011. A self-admin-
istered questionnaire covering three areas was used: (1) communication with health profes-
sionals about clinical trials, with the Center for Memory at Home (CMP) as well as with 
patients/caregivers and the general public; (2) internal organization and the existence and 
operation of a unit dedicated to trial enrollment, (3) and the evaluation of screening tools 
used in each CMRR. The survey was conducted in the following stages:
 • stage 1: development of the questionnaire on the three main areas
 • stage 2: testing of the questionnaire in a sample of five doctors
 • stage 3: making contact with the CMRR in metropolitan France 
 • stage 4: distribution of the questionnaire by mail and e-mail 
 • stage 5: responses by mail from July 1, 2011
 • stage 6: investigations closed on July 31, 2011
 • stage 7: data management and statistical analysis.
 Data Management
 Data were managed by the functional unit of clinical research and biostatistics of the 
University Hospital of Limoges. The database was stored on a server at the University Hospital 
of Limoges and met all relevant safety standards (access protected by login and password). 
Consistency checks were made during data entry. At the end of the audit period, the database 
was closed and then exported using SAS ®  software version 9 (SAS Institute, Cary, N.C., USA) 
for statistical analysis.
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 Statistical Analysis
 The descriptive analysis of continuous variables (e.g. length of experience) is presented 
as mean, standard deviation, minimum and maximum or median, first and third quartile, 
eligible and missing data by subgroup and in total. Categorical variables (e.g. sex) are present -
 ed as number and percentage (expressed at two decimal places) by subgroup and total. To 
compare subgroups based on quantitative variables, Student’s t test or analysis of variance 
(number of groups greater than two) was performed when normality was not rejected 
(Shapiro-Wilk), otherwise a nonparametric test such as Mann-Whitney or Kruskal-Wallis 
(number of groups greater than two) was preferred. To compare subgroups based on quali-
tative variables, a Pearson χ 2  test was performed, and if the theoretical numbers were low, 
Fisher’s exact test was used.
 The significance level chosen for the overall alpha risk was 5% in the bilateral situation. 
Statistical analyses were performed using SAS software version 9.2 (SAS Institute).
 Results
 Response Rate
 The participation rate was 76% (18 of 25 centers). A total of 250 questionnaires were 
sent to all medical officers, investigators or subinvestigators in CMRR (10 questionnaires per 
250 questionnaires sent
(25 CMRR)
240 valid questionnaires
(25 CMRR)
• 79 questionnaires received
• 19 CMRR
• 70 questionnaires analyzed
• 19 CMRR
• 2 questionnaires received
 by e-mail
• 2 CMRR
• 77 questionnaires received
 by mail
• 17 CMRR
• 2 questionnaires analyzed
• 2 CMRR
• 68 questionnaires analyzed
• 17 CMRR
10 questionnaires excluded
(contact not valid)
• 0 questionnaires without
 recall (0 CMRR)
• 0 questionnaires excluded
• 2 questionnaires with
 recall (2 CMRR)
• 66 questionnaires without
 recall (13 CMRR)
•   9 questionnaires excluded
 (incomplete)
• 11 questionnaires with
 recall (4 CMRR)
 Fig. 1. Flow chart of reception 
mode and questionnaire analysis. 
D
ow
nl
oa
de
d 
by
: 
H
ar
va
rd
 U
ni
ve
rs
ity
   
   
   
   
   
   
   
   
   
   
   
   
 
12
8.
10
3.
13
8.
2 
- 1
1/
19
/2
01
3 
10
:3
5:
51
 P
M
421Dement Geriatr Cogn Disord Extra 2013;3:417–425
 DOI: 10.1159/000353891 
E X T R A
 Tchalla et al.: Optimization of the Inclusion of Alzheimer’s Disease Patients in Clinical 
Trials 
www.karger.com/dee
© 2013 S. Karger AG, Basel
center). Two hundred and forty questionnaires reached the appropriate personnel and 10 
were excluded. The return rate was 32.9% and the individual response rate was 29.2% ( fig. 1 ). 
 Characteristics of the Study Population
 The largest group of respondents was aged 30–39 years, representing 47.1%. Sixty 
percent were women and half of them had a management role in a CMRR. In terms of initial 
training, neurologists were the most represented, accounting for 60%; less than 30% were 
geriatricians and less than 10% were psychiatrists ( table 1 ). The average length of practice 
of medicine was 12 years for clinical investigators and subinvestigators and 26 years among 
doctors in charge. As regards the length of experience in a CMRR, 54.3% had more than 5 
years of experience ( table 1 ).
 Communication
 In total, 87.0% of the participants stated that their center communicated with health 
professionals in general, 88.9% with medical specialists (geriatricians, neurologists and 
psychiatrists), 84.1% with nearby memory centers, 73.0% with general practitioners, and 
50.8% with independent neuropsychologists and speech therapists ( table 2 ). Regarding the 
frequency of communication, 50.8% reported contacting general practitioners at least once 
a month but the figure was only 27.4% for speech therapists, 23.8% for neuropsychologists, 
22.2% for physician specialists and 17.5% for nearby memory centers ( table 2 ). 
 Approximately 94% of the respondents communicated with patients, mostly during 
consultations (88.6%), and a few used billboards (35.7%), brochures (21.4%), newsletters 
(12.9%) or the telephone (11.4%). Collaboration with patient organizations and carers was 
effective in 75% of the cases, often involving briefings and awareness sessions (51.6%) but 
very few attended workshops (14.1%) or social events (12.5%) ( table 2) . 
 Only half of the participants (54.4%) communicated with the public occasionally or very 
often (46.9%) and mainly did so via thematic conferences (37.5%), but rarely via the Internet 
(18.8%) or audiovisual media (12.5%) ( table 2 ). 
 Internal Organization
 Approximately 78% of the participants claimed to have a specific research group in their 
CMRR. In most cases (75%), this research group had a manager and often (39%) comprised 
 Table 1.  Sociodemographic characteristics of participants of a national descriptive survey for optimizing 
inclusion of patients in clinical trials on AD
 Characteristics  Medical managers 
 (n = 10) 
 Medical investigators and 
 subinvestigators (n = 60) 
 Total 
 (n = 70) 
 Age in years 
 <30  0 1 (1.7%) 1 (1.4%) 
30  –  39 0 33 (55.0%) 33 (47.1%) 
40  –  49 2 (20.0%) 12 (20.0%) 14 (20.0%) 
50  –  59 5 (50.0%) 13 (21.7%) 18 (25.7%) 
 ≥60 3 (30.0%) 1 (1.7%) 4 (5.7%) 
 Women 5 (50.0%) 37 (61.7%) 42 (60.0%) 
 Years of medical experience  26.5  ±  6.0  12.3  ±  9.2  14.4  ±  10.1 
 Years of experience in CMRR 
 <1 1 (10.0%) 6 (10.0%) 6 (8.6%) 
1  –  5 8 (80.0%) 26 (43.3%) 26 (37.1%) 
 >5 1 (10.0%) 28 (46.7%) 38 (54.3%) 
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fewer than four members ( table 3 ). This group met regularly in most cases (82.3%). Meetings 
focused primarily on information about upcoming clinical trials (86%), the progress of trials 
already underway (85%) and multidisciplinary issues (70%). Only half of the participants 
reported receiving the minutes of meetings, including reports on the progress of enrollment. 
In 35.3% of the cases, participants reported that their center did not have a record of physician 
investigators. More than half of the participants (55%) did not have a consultation time dedi-
cated to enrollment ( table 3 ). 
 Assessment of Screening Tools 
 A total of 76.5% of the participants reported having a screening tool, but only 27.4% were 
satisfied with it. In nearly 35% of the cases, nobody was assigned to enter data, and problems 
(essentially the time taken to complete it and inadequacy of the tool) were noted in 36% of 
the cases ( table 4 ). In centers with no screening tools, 65% of the patients were recruited 
during consultations and 29% by review of the relevant records and correspondence. A total 
of 43% gave their consent for future involvement during consultations ( table 4 ).
 Discussion
 Main Results
 This study shows that several factors play a role in rendering the recruitment of AD 
patients in clinical studies inefficient and in opening a framework for improvement. Three 
quarters of all CMRR participated in our survey, and about one third of the surveyed physi-
cians responded positively. The results showed that the majority of the CMRR communicated 
 Table 2. Classification of CMRR communication parameters of a national descriptive survey for optimizing inclusion of patients 
in clinical trials on AD
 Communication parameters  Medical 
 managers
(n = 10) 
 Medical investigators 
 and subinvestigators
(n = 60) 
 Total 
(n = 70) 
 Communication with health professionals   10 (100.0%)  50 (84.8%)  60 (87.0%) 
 Communication with patients  10 (100.0%)  56 (93.3%)  66 (94.3%) 
 Collaboration with patient and carer organizations 7 (70.0%)  43 (74.1%)  50 (73.5%) 
 Collaboration with other associations 7 (70.0%)  19 (35.9%)  26 (41.9%) 
 Communication with the general public 6 (60.0%)  31 (53.5%)  37 (54.4%) 
 Table 3. Classification of CMRR internal organization parameters of a national descriptive survey for optimizing inclusion of 
patients in clinical trials on AD
 Internal organization parameters  Medical 
 managers
(n = 10) 
 Medical investigators 
 and subinvestigators
(n = 60) 
 Total
(n = 70) 
 Specific unit dedicated to clinical research  8 (80.0%)  46 (78.0%)  54 (78.3%) 
 Receiving e-mails on the progress of the inclusions  5 (62.5%)  30 (53.6%)  35 (50.7%) 
 Updated register of potential investigators or subinvestigators   6 (60.0%)  27 (46.6%)  33 (48.5%) 
 Consultation time dedicated to inclusions  8 (80.0%)  30 (50.9%)  38 (55.1%) 
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with health professionals but very irregularly. Communication with patients was also 
reported, but it was inadequate and ineffective, as was collaboration with patient associations 
and/or caregivers. A net deficit of communication with the large public is observed and the 
diffusion method was discontinued. The internal organization of the group was based on 
existing research in most cases but was active in only half of the cases. Three quarters of the 
respondents had a screening tool in their CMRR but over half were not satisfied with it. 
 Strengths
 This survey was carried out using a protocol suited to the use of a pretested question-
naire and focused on three specific areas: communication, internal organization and the 
screening tool. The diffusion method was optimal by mail and mail with a telephone reminder. 
This method maximizes the rate of participation in large-scale surveys  [11] . Our distribution 
also relies on local representatives in the centers. All CMRR in France were asked to partic-
ipate, and the response was overwhelming. 
 Limitations
 Like most national surveys, this study has some shortcomings including the participation 
rate and the lack of an individual exhaustive survey of all members of each center. The indi-
vidual response rate was relatively low but still within the acceptable range for surveys 
conducted nationally. 
 External Consistency 
 Several studies  [12–14] analyzing the predictors of optimal inclusion of patients in 
clinical trials confirm our hypothesis of internal and external testing. This study focuses on 
the factor of external health care professionals, patients and caregivers. This is an element 
that leads to substantial research on centers and the immediate environment of patients. This 
factor is associated with an OR of 4.0 and a 95% CI of 1.1–15.6  [14] . Other authors have shown 
that the involvement of carers and/or professionals with better information increased the 
inclusion rate by 27%  [15] . Consideration of the patient’s environment and appropriate 
communication are crucial in the optimization of recruitment in clinical trials with an impact 
on AD  [16] . These elements support our aim of optimizing the communication and collabo-
ration between CMRR, patient organizations and caregivers, and allowing the public access 
 Table 4. Screening tools evaluation of a national descriptive survey for optimizing inclusions of patients in clinical trials on AD
 Parameter evaluation  Medical 
 managers 
(n = 10) 
 Medical investigators 
 and subinvestigators 
(n = 60) 
 Total 
(n = 70) 
 Specific screening tools  7 (70.0%)  45 (75.0%)  52 (74.3%) 
 Specific person for entering data   5 (71.4%)  37 (82.2%)  42 (80.7%) 
 Not satisfied with this tool  1 (14.3%)  31 (68.9%)  32 (61.5%) 
 Time-consuming tools  2 (28.6%)  17 (37.8%)  19 (36.5%) 
 Unadapted tools  3 (42.9%)  15 (33.3%)  18 (34.6%) 
 Other  0 2 (4.4%) 2 (3.9%) 
 No specific screening tools  3 (30.0%)  15 (25.0%)  18 (25.7%) 
 Retrospective reading of consultation report or hospital day report  1 (33.3%)  11 (73.3%)  12 (66.7%) 
 Following consultations  2 (66.7%)  14 (93.3%)  16 (88.9%) 
 Medical staff  1 (33.3%)  11 (73.3%)  12 (66.7%) 
 Satisfied with this mode of operation  3 (100.0%)  13 (86.7%)  16 (88.9%) 
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to information, including information on clinical trials and their inclusion criteria. An elec-
tronic portal (ONRA) for all ongoing trials in French CMRR, like clinicaltrials.gov, would also 
optimize communication regarding the general public and have direct implications for famil-
iarization with research; it would also create a personal incentive for patients and families to 
contact research centers  [17, 18] . For more effective communication, the internal organi-
zation of the research center should be clearly arranged. Therefore, it is essential to establish 
clear procedures for the organization of inclusions. 
 The internal organization concerning group research should be well defined in terms of 
its mode of operation and its composition. Our study reveals that most centers have a research 
group but it is often inactive and therefore ineffective. Galvin et al.  [14] showed that inade-
quate procedures and the framework of opinion about the process of inclusions are both 
predictors of inclusion: OR 4.7, 95% CI (12–18.7), OR 6.8, 95% CI (1.4–32.3). Diebolt and 
Pletan  [19] clearly showed that the internal organization of research centers in France has 
major deficiencies particularly with regard to bureaucracy and lack of motivation of prac-
ticing physicians in the centers. They do not feel involved in the procedures because of a lack 
of staff meetings or information on research concerning upcoming clinical trials or the 
progress of trials already underway. The discrepancy between the results we obtained in this 
investigation and the perceptions of CMRR managers and physician-investigators and coin-
vestigators illustrate this lack of standardization of procedures in the same center. Apart from 
purely organizational issues, the quality of screening tools requires special attention. 
 The evaluation of screening tools performed as part of this investigation shows that they 
were available in most centers but were generally unsatisfactory. The main problems were 
the lack of personnel responsible for data entry and the inadequate functionality of the tools 
themselves. These deficiencies have resulted in time-consuming inclusions that not only 
directly reduce the speed of recruitment but also impair the ability to recruit patients meeting 
various inclusion criteria.
 Conclusion
 The information provided by this survey offers a basis for improvement in the screening 
of patients via both development of internal organization and adaptation of tools that are 
already available. This means promoting regular communication that is appropriate and 
targeted to health professionals, nearby memory centers, associations and the general public 
and thereby familiarizing the French population with clinical research in the field of AD.
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